
Verve Therapeutics’ Base Editing Therapy VERVE-102 Reduces LDL-C in Patients With HeFH and CAD
Verve Therapeutics’ VERVE-102, an investigational in vivo base editing therapy that uses a lipid nanoparticle (LNP) delivery system, has demonstrated the ability to reduce low-density lipoprotein cholesterol (LDL-C) and PCSK9 protein levels in patients …